Atezolizumab is an FDA-approved PD-L1 inhibitor that has shown improved progression-free survival and overall survival when used in combination with nabpaclitaxel for metastatic triple negative breast cancer [95]. The gene discussed is CD274; the disease is triple-negative breast carcinoma.